We present the case of a patient with extensive Klippel-Trenaunay Syndrome and underlying Kasabach Merritt Syndrome who encountered extensive intraoperative bleeding requiring a massive transfusion of greater than thirty liters of blood and blood products. This case highlights the coagulation challenges posed not only by massive transfusion but also by Klippel-Trenaunay Syndrome with concomitant Kasabach-Merritt Syndrome. This case also notes the value of massive transfusion protocols, while keeping in mind that these have been created from retrospective data.
CASE DESCRIPTION
A seventeen-year-old male with Klippel-Trenaunay Syndrome with extensive involvement of his right lower extremity was admitted to a tertiary care facility for management of a painful nonunion resulting from a right femoral fracture. He was scheduled for a transfemoral amputation, a procedure indicated for his increasing chronic right leg pain and syncope with standing secondary to extensive venous pooling (Figures 1 and 2 ). He required chronic opioids for his right leg pain. This patient also suffered from Kasabach-Merritt Syndrome, a chronic consumptive coagulopathy that can be associated with Klippel-Trenaunay Syndrome. Upon admission, his coagulation studies were: INR (International Normalized Ratio) of 1.3 (normal = 0.9-1.2), Activated Partial Thromboplastin Time (aPTT) of 32 seconds (normal = 21-33 sec), Fibrinogen 125 mg/dL (normal = 175-430 mg/dL) and Platelets 108 (x10^9/L; normal = 150-450 x10^9/L).
Under general anesthesia, a transfemoral amputation was performed, though complicated by an estimated blood loss of 5700 mL. Difficulty with hemostasis was attributed to non-compressible bleeding sites, underlying KasabachMerritt Syndrome and difficulty oversewing the venous malformations. In the thirteen postoperative days following the initial amputation, he had persistent and progressive sanguinous oozing from the surgical wound requiring increasingly frequent blood and blood product transfusions for blood-loss anemia and coagulopathy. The Anesthesia Inpatient Pain Service was consulted for rapidly increasing right stump pain and a subsequent dramatically accelerated opioid consumption. He described the pain as being ten on a ten-point pain scale, and was administered a total of 39 mg of intravenous (IV) hydromorphone over 2.5 hours without significant improvement.
The patient returned to the operating suite for wound examination and hematoma evacuation. Hemostasis was attained and he was transferred to the surgical intensive care unit. However, he continued to have persistent sanguinous oozing requiring further blood and blood product transfusions for both anemia and persistent coagulopathy. Over the next 12 hours he received seven units of packed red blood cells and one unit of filtered and washed red blood cells from blood salvage system. As the patient was not responding appropriately to blood transfusions he returned early the following morning to the operating suite for another wound examination and attempt at hematoma evacuation, irrigation and debridement. Preoperatively, his labs showed: Hgb 7.9 g/dL, Platelets 88 (x 10^9)/L, INR The patient described has provided permission to present this case. Potential complications of massive transfusion include: hypocalcemia, hyperkalemia, metabolic acidosis, coagulopathy, hypothermia, transfusion related acute lung injury (TRALI), transfusion associated circulatory overload (TACO), and abdominal compartment syndrome. Coagulopathy from massive transfusion may have several causes including hypothermia, dilutional thrombocytopenia, dilutional coagulation deficiency, dilutional fibrinogen deficiency and DIC. 4, 5 In addition to the dilutional coagulopathy of massive transfusion, the patient presented in this report had a concomitant consumptive coagulopathy secondary to Kasabach-Merritt syndrome.
There is no clear consensus for the ratio of blood products to be administered during massive transfusion. The goal of administering a proper ratio of blood products is to prevent dilutional coagulopathy and to compensate for blood component consumption. A patient can lose up to 70% of their coagulation factors before developing a clinical bleeding diathesis, so the goal is the ensure the levels of coagulation factors remain above 30% of normal. A coagulation factor level of 30% correlates to a PT (prothrombin time) and aPTT of 1.5 times normal. Similarly, clinically significant coagulopathy occurs when fibrinogen levels fall below 100 mg/dL or platelets fall below 80 x 10 9 /L. 4 The transfusion ratios used during the primary procedure described in this case were RBC:FFP:Platelets of 1:0.84:0.62 (or FFP:RBC of 1:1.2, and Platelets:RBC of 1:1.6). Numerous retrospective studies have demonstrated improved outcomes with increased platelet-to-RBC ratio and increased FFP-to-RBC ratio. Perhaps the most compelling data is from a multicenter retrospective study by Holcomb et al. which showed a significant association between increased FFP-to-RBC ratios (>1:2) and increased platelet-to-RBC ratios (>1:2) with increased survival at 24 hours and 30 days from admission. 6 Massive transfusion protocols are associated with decreased pneumonia, respiratory failure, sepsis, multiorgan failure and abdominal compartment syndrome. 7 Likewise, a review by Ketchum et al. found a reduction in coagulopathy from massive transfusion if FFP and platelets were administered early in resuscitation. 8 These retrospective studies are hindered by survival bias.
Currently, prospective studies on the effect of massive transfusion ratios are lacking and are necessary to guide future massive transfusion recommendations.
Regardless of the precise ratio used during massive transfusion, the clinician must be aware of potential coagulopathy and monitor for this consequence of massive transfusion. Several groups recommend following basic coagulation studies including PT, aPTT, Fibrinogen and platelet levels throughout massive transfusion. In order to follow a patient's more global coagulation function, one could follow serial Thromboelastograms TM (TEG). 4, 9 PT, aPTT, Fibrinogen, platelets and TEG TM can be used to guide necessary blood product replacement. 4, 5, 6 Blood component ratios are useful during massive transfusion because during a massive resuscitation by the time the laboratory values are available for assessment the patient has often lost and received a large amount of blood and blood products. In this scenario, the laboratory values may not reflect the patient's current coagulation status.
A final point is effective multi-specialty communication and coordination of care was essential for success in this case. Four primary services were involved in the operating suite including Anesthesiology, Orthopedic Surgery, Vascular Surgery and General Surgery. At times, when the patient was hypovolemic, the surgical services would pause and hold pressure on the bleeding surfaces and underlying vascular structures in order to allow time for resuscitation. At the conclusion of the case, there was a concerted diagnosis and very rapid treatment of the patient's abdominal compartment syndrome. Without open communication and collaboration both before and during this case, the outcome may not have been so positive. References
